Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. Among authors: naldi l. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.
Pezzolo E, Ortoncelli M, Ferrucci SM, Guanti MB, Schena D, Napolitano M, Rossi M, Foti C, D'Amico D, Amoruso GF, Morrone P, Ribero S, Barei F, Biagi M, Pascucci E, Patruno C, Calzavara Pinton P, Romita P, Gargiulo L, Narcisi A, Naldi L. Pezzolo E, et al. Among authors: naldi l. J Clin Med. 2024 Jan 18;13(2):553. doi: 10.3390/jcm13020553. J Clin Med. 2024. PMID: 38256686 Free PMC article.
Lasers for the treatment of psoriasis: a systematic review.
Heidemeyer K, Kulac M, Sechi A, Cazzaniga S, Naldi L. Heidemeyer K, et al. Among authors: naldi l. Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):717-744. doi: 10.1080/1744666X.2023.2205640. Epub 2023 Apr 28. Expert Rev Clin Immunol. 2023. PMID: 37079360
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: naldi l. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
Pezzolo E, Gambardella A, Guanti M, Bianchelli T, Bertoldi A, Giacchetti A, Donini M, Argenziano G, Naldi L. Pezzolo E, et al. Among authors: naldi l. J Am Acad Dermatol. 2023 Aug;89(2):430-432. doi: 10.1016/j.jaad.2023.04.056. Epub 2023 May 5. J Am Acad Dermatol. 2023. PMID: 37150301 No abstract available.
495 results